Sellas rises on FDA "fast track" tag for cancer therapy

Sellas Life Sciences

30/10/2023 13:51

** Shares of therapy developer Sellas Life Sciences Group
 SLS.O  rise ~9% to $1.02 
    ** Co says the U.S FDA grants "Fast Track" designation to
its therapy for a type of lymph system cancer called Peripheral
T-cell Lymphomas (PTCL)
    ** FDA's "fast track" status is intended to expedite the
review of drug candidates being developed to treat serious
conditions
    ** Including session's move, shares down ~57.6% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))